TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Up 3,278.9% in February

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the target of a large growth in short interest in February. As of February 15th, there was short interest totalling 128,400 shares, a growth of 3,278.9% from the January 31st total of 3,800 shares. Based on an average daily trading volume, of 210,100 shares, the short-interest ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reduced their price objective on TC Biopharm from $112.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, December 6th.

TC Biopharm Stock Performance

TCBP stock traded up $0.08 during midday trading on Thursday, reaching $2.16. 57,094 shares of the company’s stock traded hands, compared to its average volume of 283,236. TC Biopharm has a 52 week low of $1.91 and a 52 week high of $523.20. The firm’s fifty day moving average price is $6.67 and its 200-day moving average price is $37.58.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.